Program
Sinovac PCV13
Also written as “Sinovac PCV13 lot 1”, “Sinovac PCV13 lot 2” and “Sinovac PCV13 lot 3”.
Its studies are mostly in Pneumococcal Infections, led by Sinovac Biotech.
Furthest: phase 3, since Sep 26, 20244 company-led studies, 3 open or runningNext primary completion: Mar 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sinovac Biotech | 43 open or running | phase 3since Sep 26, 2024 | Dec 13, 2023 | Mar 2027phase 3 · NCT07832500 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 13, 2023First study: phase 1 study in Pneumococcal InfectionsFirst studyNCT06183216 · 140 enrolled · China
- Sep 26, 2024Phase 3 study in Pneumococcal InfectionsNCT06617715 · 3,080 planned · China
- May 11, 2026Phase 3 study in Pneumococcal Infectious DiseasesNCT07593924 · 500 planned · Philippines
- Sep 16, 2026Phase 3 study in Pneumococcal Infectious DiseasesNCT07832500 · 1,125 planned · China
Ahead
- Mar 2027Primary completion: phase 3 study in Pneumococcal Infectious DiseasesNCT07832500
- Jul 2027Primary completion: phase 3 study in Pneumococcal Infectious DiseasesNCT07593924
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07832500Pneumococcal Infectious Diseases · China | 3 | Not yet recruiting | Mar 2027 | 1,125 |
| NCT07593924Pneumococcal Infectious Diseases · Philippines | 3 | Not yet recruiting | Jul 2027 | 500 |
| NCT06617715Pneumococcal Infections · China | 3 | Recruiting | May 12, 2026 | 3,080 |
| NCT06183216Pneumococcal Infections · China | 1 | Completed | Mar 26, 2025 | 140 |
How it is read
Names in the registry
- “Sinovac PCV13”, 3 entries
- “Sinovac PCV13 lot 1”, 1 entry
- “Sinovac PCV13 lot 2”, 1 entry
- “Sinovac PCV13 lot 3”, 1 entry
Conditions, from the studies’ own filings
- Pneumococcal Infections, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.